The biochip market in North America is expected to reach a projected revenue of US$ 16,181.4 million by 2033. A compound annual growth rate of 10.1% is expected of North America biochip market from 2026 to 2033.
The North America biochip market generated a revenue of USD 7,280.7 million in 2025.
The market is expected to grow at a CAGR of 10.1% from 2026 to 2033.
In terms of segment, dna chips was the largest revenue generating type in 2025.
Lab-on-chip is the most lucrative type segment registering the fastest growth during the forecast period.
Country-wise, U.S. is expected to register the highest CAGR from 2026 to 2033.
North America data book summary
Market revenue in 2025
USD 7,280.7 million
Market revenue in 2033
USD 16,181.4 million
Growth rate
10.1% (CAGR from 2026 to 2033)
Largest segment
Dna chips
Fastest growing segment
Lab-on-chip
Historical data covered
2021 - 2024
Base year for estimation
2025
Forecast period covered
2026 - 2033
Quantitative units
Revenue in USD million
Market segmentation
DNA Chips, Lab-on-chip, Tissue Arrays, Protein Chips, Cell Arrays
Key market players worldwide
Agilent Technologies Inc, PerkinElmer, Illumina Inc, Bio-Rad Laboratories Inc, Standard BioTools Inc, GE HealthCare Technologies Inc Common Stock, Thermo Fisher Scientific Inc, Qiagen NV, Randox
Other key industry trends
In terms of revenue, North America region accounted for 47.5% of the global biochip market in 2025.
Globally, North America is projected to lead the regional market in terms of revenue in 2033.
Asia Pacific is the fastest growing regional market and is projected to reach USD 7,272.5 million by 2033.
North America held a significant share of the global biochip market, and its growth can be attributed to factors such as increasing efforts of pharmaceutical and biotechnology companies for drug development, advancement in proteomics, and growing demand for personalized medicine.
Moreover, the presence of a substantial number of players in the region and high investment in R&D related to precision medicine & advanced clinical diagnostics are some of the factors responsible for the largest revenue share of the region.
The presence of key market players such as Thermo Fisher Scientific, Illumina, and Agilent Technologies, which offer a broad range of microarrays for genotyping & gene expression applications, have supported North America’s dominance in the market in the past years.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Biochip Market will help companies and investors design strategic landscapes.
Dna Chips was the largest segment with a revenue share of 44.05% in 2025.
Horizon Databook has segmented the North America biochip market based on dna chips, lab-on-chip, tissue arrays, protein chips, cell arrays covering the revenue growth of each sub-segment from 2021 to 2033.
North America held a significant share of the global biochip market, and its growth can be attributed to factors such as increasing efforts of pharmaceutical and biotechnology companies for drug development, advancement in proteomics, and growing demand for personalized medicine.
Moreover, the presence of a substantial number of players in the region and high investment in R&D related to precision medicine & advanced clinical diagnostics are some of the factors responsible for the largest revenue share of the region.
The presence of key market players such as Thermo Fisher Scientific, Illumina, and Agilent Technologies, which offer a broad range of microarrays for genotyping & gene expression applications, have supported North America’s dominance in the market in the past years.
North America Biochip Market Type Outlook (Revenue, USD Million , 2021-2033)
DNA Chips
Protein Chips
Lab-on-chip
Tissue Arrays
Cell Arrays
North America Biochip Market End Use Outlook (Revenue, USD Million , 2021-2033)
Biotechnology and Pharmaceutical Companies
Hospitals and Diagnostics Centers
Academic & Research Institutes
Others
Reasons to subscribe to biochips market databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of biochips market databook
Our clientele includes a mix of biochips market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America biochips market, including forecasts for subscribers. This continent databook contains high-level insights into North America biochips market from 2021 to 2033, including revenue numbers, major trends, and company profiles.